Overview

Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of sorafenib in the neoadjuvant setting in patients with primary breast cancer
Phase:
Phase 2
Details
Lead Sponsor:
German Breast Group
Collaborator:
Bayer
Treatments:
Niacinamide
Sorafenib